GALvanizing Alzheimer’s disease therapy to combat the inflamed brain
Leire Abalde-Atristain
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Email: labalde1{at}jhmi.edu
See allHide authors and affiliations
Science Translational Medicine 08 May 2019: Vol. 11, Issue 491, eaax8310 DOI: 10.1126/scitranslmed.aax8310
Leire Abalde-Atristain
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Email:
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Email: labalde1{at}jhmi.edu
GALvanizing Alzheimer’s disease therapy to combat the inflamed brain
By Leire Abalde-Atristain
Science Translational Medicine
Galectin-3 is elevated in patients with Alzheimer’s disease (AD), and its deletion reduces neuroinflammation and β-amyloid burden in a mouse model of AD.
GALvanizing Alzheimer’s disease therapy to combat the inflamed brain
By Leire Abalde-Atristain
Science Translational Medicine
Galectin-3 is elevated in patients with Alzheimer’s disease (AD), and its deletion reduces neuroinflammation and β-amyloid burden in a mouse model of AD.